4th Oct 2024 19:10
Graft Polymer (UK) PLC - London-based developer and producer of alloyed polymers, biological supplements and drug delivery systems - Selects drug discovery solutions provider Eurofins Discovery to carry out initial testing for its co-lead aminoindane series, to begin immediately. First announced in July, the programme is under joint development with Awakn Life Sciences Corp and seeks to develop next-generation medicines targeting trauma-related mental health conditions like Post-Traumatic Stress Disorder. The condition affects about 20 million adults in the US, UK, and key European markets, Graft Polymer notes. Tests will assess the potential of Graft's aminoindane series for serotonin, dopamine and noradrenaline reuptake inhibition. Selection marks a significant milestone, the company says, and follows its August announcement that it filed a new provisional patent in the US after Awakn "identified two aminoindane chemical series as co-leads for further development". Read More
